Cwm LLC Has $712,000 Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Cwm LLC boosted its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 68.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,454 shares of the medical research company’s stock after buying an additional 4,248 shares during the quarter. Cwm LLC’s holdings in Exact Sciences were worth $712,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Exact Sciences by 16.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 89,196 shares of the medical research company’s stock valued at $6,160,000 after purchasing an additional 12,349 shares during the period. Thompson Investment Management Inc. lifted its stake in shares of Exact Sciences by 13.1% in the 1st quarter. Thompson Investment Management Inc. now owns 160,584 shares of the medical research company’s stock valued at $11,090,000 after purchasing an additional 18,595 shares during the period. Vanguard Group Inc. lifted its stake in shares of Exact Sciences by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 17,559,751 shares of the medical research company’s stock valued at $1,299,070,000 after purchasing an additional 115,058 shares during the period. CANADA LIFE ASSURANCE Co lifted its stake in shares of Exact Sciences by 5.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 207,364 shares of the medical research company’s stock valued at $14,361,000 after purchasing an additional 10,356 shares during the period. Finally, Profund Advisors LLC lifted its stake in shares of Exact Sciences by 239.8% in the 2nd quarter. Profund Advisors LLC now owns 78,589 shares of the medical research company’s stock valued at $3,320,000 after purchasing an additional 55,459 shares during the period. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EXAS. Wells Fargo & Company began coverage on Exact Sciences in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price target on the stock. Benchmark cut their price target on Exact Sciences from $91.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Stifel Nicolaus lowered their price objective on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Piper Sandler upped their price objective on shares of Exact Sciences from $75.00 to $85.00 and gave the company an “overweight” rating in a research report on Thursday, September 12th. Finally, BTIG Research lowered their price objective on shares of Exact Sciences from $80.00 to $70.00 and set a “buy” rating for the company in a research report on Wednesday, June 26th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $78.38.

Exact Sciences Price Performance

EXAS stock opened at $71.93 on Friday. The stock has a 50-day moving average price of $64.58 and a two-hundred day moving average price of $56.76. The stock has a market cap of $13.27 billion, a PE ratio of -54.49 and a beta of 1.27. The company has a current ratio of 2.17, a quick ratio of 1.98 and a debt-to-equity ratio of 0.73. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. The firm had revenue of $699.26 million during the quarter, compared to analysts’ expectations of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The company’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.45) EPS. Equities analysts forecast that Exact Sciences Co. will post -0.87 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Brian Baranick sold 929 shares of the firm’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the transaction, the executive vice president now owns 12,758 shares in the company, valued at $893,060. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.36% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.